Fulcrum Therapeutics Inc
(NAS:FULC)
$
9.17
0.38 (4.32%)
Market Cap: 572.22 Mil
Enterprise Value: 308.09 Mil
PE Ratio: 0
PB Ratio: 2.09
GF Score: 53/100 - Q1 2024 Fulcrum Therapeutics Inc Earnings Call TranscriptMay 13, 2024$7.35 (-1.61%)Earnings
- Q4 2023 Fulcrum Therapeutics Inc Earnings Call TranscriptFeb 27, 2024$10.18 (+4.62%)Earnings
- Q3 2023 Fulcrum Therapeutics Inc Earnings Call TranscriptNov 07, 2023$4.29 (+19.50%)Earnings
- Q2 2023 Fulcrum Therapeutics Inc Earnings Call TranscriptAug 03, 2023$3.85 (+0.79%)Earnings
- Q1 2023 Fulcrum Therapeutics Inc Earnings Call TranscriptMay 15, 2023$3.64 (+11.31%)Earnings
- Q4 2022 Fulcrum Therapeutics Inc Earnings Call TranscriptMar 09, 2023$4.82 (-23.00%)Earnings
- Fulcrum Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 12, 2023
- Fulcrum Therapeutics Inc at Bank of America Biotech SMID Cap Conference TranscriptDec 08, 2022
- Fulcrum Therapeutics Inc at Credit Suisse Healthcare Conference TranscriptNov 08, 2022
- Q3 2022 Fulcrum Therapeutics Inc Earnings Call TranscriptNov 08, 2022$6.45 (+14.97%)Earnings
- Fulcrum Therapeutics Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 14, 2022
- Q2 2022 Fulcrum Therapeutics Inc Earnings Call TranscriptAug 11, 2022$7.57 (-2.45%)Earnings
- Fulcrum Therapeutics Inc To Review Initial FTX-6058 Data And Provide Program Update Call TranscriptJun 10, 2022
- Fulcrum Therapeutics Inc at Bank of America Healthcare Conference TranscriptMay 12, 2022
- Q1 2022 Fulcrum Therapeutics Inc Earnings Call TranscriptMay 09, 2022$7.66 (-11.24%)Earnings
- Fulcrum Therapeutics Inc To Discuss Unmet Need In FSHD, REACH Trial And Key Measures Of Disease Progression Call TranscriptMar 24, 2022
- Q4 2021 Fulcrum Therapeutics Inc Earnings Call TranscriptMar 03, 2022$11.7 (+5.41%)Earnings
- Fulcrum Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2022
- Fulcrum Therapeutics Inc To Discuss Phase 1 Clinical Trial of FTX-6058 Call TranscriptDec 06, 2021
- Fulcrum Therapeutics Inc at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 11, 2021
- Q3 2021 Fulcrum Therapeutics Inc Earnings Call TranscriptNov 04, 2021$21.15 (+3.27%)Earnings
- Fulcrum Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 09, 2021
- Q2 2021 Fulcrum Therapeutics Inc Earnings Call TranscriptAug 10, 2021$18.77 (+125.33%)Earnings
- Fulcrum Therapeutics Inc Annual FSHD Society International Research Congress- Corporate Call TranscriptJun 24, 2021
- Fulcrum Therapeutics Inc at Bank of America Global Research Healthcare Conference (Virtual) TranscriptMay 13, 2021
- Q1 2021 Fulcrum Therapeutics Inc Earnings Call TranscriptMay 06, 2021$10.58 (+5.06%)Earnings
- Q4 2020 Fulcrum Therapeutics Inc Earnings Call TranscriptMar 04, 2021$12.5 (-14.32%)Earnings
- Fulcrum Therapeutics, Inc. - Special Call TranscriptDec 15, 2020
- Q3 2020 Fulcrum Therapeutics Inc Earnings Call TranscriptNov 10, 2020$10.94 (+1.11%)Earnings
- Q2 2020 Fulcrum Therapeutics Inc Earnings Call TranscriptAug 11, 2020$8.9 (-48.01%)Earnings
- Fulcrum Therapeutics, Inc. - Special Call TranscriptJun 10, 2020
- Fulcrum Therapeutics Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) TranscriptMay 14, 2020
- Q1 2020 Fulcrum Therapeutics Inc Earnings Call TranscriptMay 13, 2020$16.48 (+10.53%)Earnings
- Q4 2019 Fulcrum Therapeutics Inc Earnings Call TranscriptMar 05, 2020$18.5 (+2.78%)Earnings
- Q3 2019 Fulcrum Therapeutics Inc Earnings Call TranscriptNov 14, 2019$7.64 (-3.29%)Earnings
Fulcrum Therapeutics Inc at Bank of America Healthcare Conference Transcript
May 12, 2022 / 06:20PM GMT
Release Date Price:
$7.57
(+5.14%)
Tazeen Ahmad
BofA Securities, Research Division - MD in Equity Research & Research Analyst
Thanks, everybody. Welcome to the Bank of America Healthcare Conference. I'm Tazeen Ahmad. I'm one of the senior SMID biotech analysts here at the bank. It's my pleasure to have our next presenting company, Fulcrum Therapeutics, with me. Sitting on stage are several members of the management team. We've got Bryan. We've got Judith. We've got Paul.
I'll let you introduce yourselves. And then maybe, Bryan, could you give us a couple of minute overview of the company, your platform and some of your key recent updates? And then we can go through into Q&A if that works.
Bryan E. Stuart
Fulcrum Therapeutics, Inc. - President, CEO & Director
Yes, absolutely. That would be great. So Bryan Stuart, the CEO of Fulcrum.
Judith A. Dunn;Paul Bruno
Fulcrum Therapeutics, Inc. - President of Research & Development;Fulcrum Therapeutics, Inc. -
I'm Judy Dunn, President of R&D.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)